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In normal brain, the side population (SP) phenotype is
generated by ABC transporter activity and identifies
stem cell and endothelial cell subpopulations by
dye exclusion. By drug efflux, the ABCG2 transporter
provides chemoresistance in stem cells and contrib-
utes to the blood brain barrier (BBB) when active in
endothelial cells. We investigated the SP phenotype
of mouse and human gliomas. In glioma endothelial
cells, ABC transporter function is impaired, corre-
sponding to disruption of the BBB in these tumors.
By contrast, the SP phenotype is increased in nonen-
dothelial cells that form neurospheres and are highly
tumorigenic. In this cell population, Akt, but not its
downstream target mTOR, regulates ABCG2 activity,
and loss of PTEN increases the SP. This Akt-induced
ABCG2 activation results from its transport to the
plasma membrane. Temozolomide, the standard
treatment of gliomas, although not an ABCG2
substrate, increases the SP in glioma cells, especially
in cells missing PTEN.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most prevalent and
aggressive form of primary brain tumor. The infiltrative growth
of glioma cells and their resistance to standard therapy have
limited the development of successful treatment. In recent years,
numerous studies have reported the presence of stem cells in
solid tumors referred to as cancer stem-like cells (Regenbrecht
et al., 2008; Yuan et al., 2004). Cancer stem-like cells represent
a population of drug-resistant cells that can survive treatment
and repopulate the tumor. These data led to new paradigms of
tumorogenesis and chemotherapy focusing on tumor initiation
and resistance of cancer stem-like cells to chemotherapeutic
agents and radiation (Hambardzumyan et al., 2008a). The under-
lying mechanisms for such resistance have been attributed to
their greater capacity for DNA-damage repair, activation of226 Cell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc.survival pathways (Bao et al., 2006; Hambardzumyan et al.,
2008b), and overexpression of ATP-binding cassette trans-
porters (ABC transporter) (Dean et al., 2005).
ABC transporters belong to a superfamily of membrane
pumps that use ATP hydrolysis to efflux various endogenous
compounds and xenobiotics from the cell (Szakacs et al.,
2006). These proteins participate in tumor resistance by actively
transporting drugs across the cell membrane, serving to protect
cells from chemotherapeutic agents (Donnenberg and Donnen-
berg, 2005). ABCB1, ABCC1, and ABCG2 are the three main
multidrug-resistance genes overexpressed in multiple cancers.
In addition to the efflux of drugs, these pumps also possess
the ability to exclude fluorescent dyes, such as the Hoechst
33342. Stem cells are frequently identified as the ‘‘side popula-
tion’’ (SP) by flow cytometry based on ABCG2-mediated efflux
of Hoechst dye (Goodell et al., 1996). Stem cells can be isolated
by FACS sorting to select cells that exhibit low level of Hoechst
fluorescence intensity. SP cells were first isolated from bone
marrow and more recently from various solid tumors and cell
lines (Wu and Alman, 2008). These cells are pluripotent and
have greater growth capacity and resistance to cytotoxic drugs
as compared to non-SP cells (Hirschmann-Jax et al., 2004).
Moreover, when isolated from solid tumors, SP cells are more
tumorigenic after injection into nude mice (Ho et al., 2007; Patra-
wala et al., 2005).
In addition to their presence in normal cells and neoplastic
stem cells, ABC transporters are even more active in brain endo-
thelial cells, contributing to the blood-brain barrier (BBB) and
playing a pivotal role in detoxification (Dean et al., 2005). This
biological activity is critical with regard to treatment of brain
tumor patients where drug penetration into the brain is limited
by ABC transporter function in endothelial cells. Chemotherapy
efficacy is further limited by ABCG2 expression in the cancer
stem-like cells population that presumably repopulates the
tumor after therapy (Robey et al., 2007).
Although much is known about the SP phenotype and ABC
function in stem cells, several key questions remain unanswered
regarding the role of ABCG2 in glioma biology. For example,
what role does ABCG2 function have in the loss of BBB integrity
in malignant gliomas? How do genomic alterations associated
with glioma progression, such as loss of the tumor suppressor
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such as temozolomide, regulate ABCG2 function in cancer
stem-like cells? Further, can the SP phenotype and ABCG2
activity be used as a marker for stem-like cells in gliomas, and
how do genomic and therapeutic events modify its function?
Finally, can these issues be modeled in mice?
In order to investigate the role of ABCG2 function in the glioma
BBB and glioma cancer stem-like cells, we chose a well-charac-
terized mouse model for glioma. We used PDGF-induced
gliomas generated by the RCAS-tv-a system (Shih et al., 2004)
where concomitant deletion of PTEN can be achieved by
delivery of the RCAS-Cre virus (Hu et al., 2005). In this study,
we extend previous findings linking the stem cell properties of
the side population and ABCG2 function to glioblastoma mouse
models.We confirm the high tumorigenicity of SP cells, their self-
renewal ability, and their resistance to chemotherapy. We also
verify that the SP phenotype, which results from ABCG2 activity,
is a stem cell marker for glioma cells. We show that regulation of
ABCG2 function and localization to the plasma membrane are
achieved by Akt. In the present study of gliomas in vivo, we found
loss of ABC transporter function in glioma endothelial cells,
correlating with the loss of the BBB integrity seen in glioma
patients. Further, we provide the first evidence that loss of
PTEN increases the SP phenotype of glioma cancer stem-like
cells. In addition, temozolomide increases the SP fraction, espe-
cially in cells lacking PTEN. We show that temozolomide, while
not a substrate for ABCG2, enriches the fraction of glioma cells
with stem-like characteristics and elevated O6-methylguanine
DNA methyltransferase (MGMT) expression. Finally, we report
a more detailed mechanism of ABCG2 regulation: the PI3K/Akt
pathway, but not the downstream target of Akt mTOR, specifi-
cally modulates the transporter’s activity and also extend these
observations to human cancer stem-like cells.
RESULTS
Immunolocalization of ABCG2 in Normal Brain
and PDGF-Induced Gliomas
The expression of ABC transporters at the BBB has been
proposed as the major factor limiting drug penetration inside
the brain with the consequent multidrug resistance of tumors.
We initially used immunofluorescence staining of tissue samples
to determine the location of ABCG2 expression in normal mouse
brain and in brains harboring PDGF-induced gliomas. Consistent
with previous reports, immunohistochemical analyses of normal
brain sections revealed strong ABCG2 expression at the luminal
side of capillary endothelial cells. Such immunoreactive cells
were distributed throughout the brain, including the cortex, white
matter tract, and cerebellum (see Figure S1A available online). In
PDGF-induced glioma, ABCG2 localized to the large vessels of
the tumor where it coexpressed with the endothelial cell marker
VonWillebrand factor (vWF) (Figure 1A). Flow cytometry analysis
forABCG2 function usually identifies the sidepopulation asa very
small fraction of cells in tumors; consistent with this, we found
a small percentage of tumor cells expressing ABCG2. However,
tumor samples exhibited some regions of cells positive for both
ABCG2 and nestin, which were not endothelial cells (negative
for vWF) (Figure 1B). These observations suggested that both
endothelial cells and progenitor tumor cells express ABCG2.Identification of a Side Population in Normal Brain
and PDGF-Induced Gliomas
To characterize the cells that actively contribute to the SP pheno-
type, we performed a Hoechst dye exclusion assay on cells iso-
lated from the normal brain cortex of five different mice, as well
as cells isolated from PDGF-induced tumors. As most cells accu-
mulate Hoechst 33342, SP cells can be isolated by dual-wave-
length flow cytometry based of their ability to efflux this dye,
a process that requires the action of the ABC transporters. We
identified a side population among cells isolated from normal
mouse brain cortex (Figure 1C). This SP fraction was generally
small, ranging from0.5%to0.8%of total cells, andwasaccompa-
nied by a distinct population of cells termed the ‘‘low side popula-
tion’’ (lowSP). LowSPcellswerepresent in large numbers (c.a 6%
to 8%) and very actively excluded Hoechst 33342. Incubation in
the presence of 100 mM verapamil, known to block ABC trans-
porter activity, abolished the lowSPand part of the SP. In contrast
towhatwas seenwith normal brain tissue, cells isolated fromsolid
tumor exhibited a different pattern of Hoechst dye exclusion, with
a uniform SP representing 4% to 8% of the total population (Fig-
ure 1C). While a low SP has already been described in normal
brain, its relative absence in the tumor samples was unexpected
(Mouthon et al., 2006). Q-RT-PCR for ABCG2 confirmed the high
level of expression of ABCG2 transporter in the low SP and SP,
i.e., 30- and 10-fold increases, respectively, as compared to the
main population (MP), confirming that ABCG2 contributes to the
SP phenotype (Figure 1D). The ABCB1a (MDR1a) transporter
was also found to be highly expressed in the low SP and SP frac-
tions, while the level of ABCB1b (MDR1b) and ABCC1 (MRP1)
transporters was not elevated in these fractions (Figure S1B).
Cell Surface Phenotype of SP Cells from Normal Brain
and PDGF-Induced Gliomas
To further characterize the cells present within the SP and low
SP, cells isolated from normal mouse brain or PDGF-induced
gliomas were subjected to double staining for Hoechst and
various cell surface markers. Staining of cells isolated from
normal brain cortex for CD31, a marker of endothelial cells,
showed that up to 70% of the positive cells are concentrated
into the low SP area (Figure 1E). This observation indicates
that the low SP is highly enriched in endothelial cells and is
consistent with the immunolocalization of ABCG2 at the vascu-
lature described above. As CD133 has been proposed to be
a marker of endothelial progenitor cells, hematopoietic stem
cells, and neuronal stem cells in normal and malignant tissues,
we looked at the expression profile of CD133 within the Hoechst
populations. In normal brain, CD133+ cells were located mainly
in the low SP, where a high proportion of these cells were also
positive for CD31, indicating an endothelial cell origin (Figure 1E).
In contrast to the normal brain,where CD31 cellswere predom-
inantly found in the low SP, the CD31+ cells in gliomas were
spread over the low SP, SP, and MP, implying a reduction of
ABC transporter function in the endothelial cells in these tumors.
(Figure 1E). The CD133+ cells were more abundant in PDGF-
induced gliomas as compare to normal brain (4% ± 1.5 versus
12% ± 3.3) and were also distributed across the three Hoechst
populations.Results forquantificationof thestaining inSP fraction
isolated from tumor-bearing mice are presented in Figure 1F.
Up to 35% of the cells were endothelial cells (CD31+ andCell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc. 227
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Finally, 15%of thecells labeled for theoligodendrocyteprogenitor
marker A2B5, and 4% labeled for the microglia marker CD11b.
Based on immunostaining, a majority of tumor cells expressing
ABCG2 were also nestin positive. These data further indicate
that the SP population of cells is composed of both endothelial
cells and cells expressing stem and progenitor markers. Previous
reports have documented that the BBB is disrupted in human and
animal models of brain tumors resulting in leakage of IV contrast
material into tumors (McConville et al., 2007; Provenzale et al.,
2005). In line with this observation, the absence of low SP in cells
isolated from solid tumors suggests that their endothelial cells
possess lower levels of ABC transporter expression or activity.
This is supported by the wide distribution of CD31+ cells among
the SP and MP, demonstrating that endothelial cells indeed
possess a lower capacity to efflux the Hoechst dye.
SP Cells Are Enriched for Neurosphere-Forming Ability
We then determined the extent that SP cells behave as stem
cells. After Hoechst staining, the three populations from four
Figure 1. ABCG2 Localizes in Vasculature
and Progenitor Cells of PDGF-Induced
Gliomas and Identifies Side Population
Cells
(A) ABCG2 (red) localizes in blood vessels of
gliomas, where it is coexpressed with Von Wille-
brand factor (vWF) (green); DAPI is counterstained
in blue.
(B) ABCG2 (red), vWF (purple), and nestin (green)
show that some nestin-immunoreactive cells are
positive for ABCG2 in both endothelial cells and
tumor progenitor cells.
(C) Hoechst 33342 dye exclusion assay on cells
isolated from normal brain cortex identifies a SP
and low SP fraction, while a uniform SP fraction
is detected in PDGF-induced gliomas. Incubation
with verapamil abolished the SP and low SP; MP
corresponds to the main population.
(D) Q-RT-PCR confirms high expression levels of
ABCG2 in the low SP and SP as compared to
the MP in PDGF-induced tumors. Error bars are
mean ± SEM.
(E) Cell surface phenotype of SP cells shows that
in normal brain, the majority of low SP cells are
positive for CD31 and/or CD133. In tumor
samples, the CD31+ and CD133+ cells are spread
over the three populations, indicating a lower
ability of endothelial cells to exclude the dye.
(F) Quantificationof double staining for Hoechst and
cell surface markers (CD31, CD133, A2B5, and
CD11b) in SP cells isolated from mouse gliomas.
Error bars are mean ± SEM.
different brains were separated by FACS
sorting and equal numbers of cells were
cultured in neurosphere medium (supple-
mented with EGF and bFGF). In all cases,
the SP cells from gliomas formed more
neurospheres than the MP and low SP
cells (Figure 2A). By contrast, none of the
three cell populations isolated from adult
normal brain cortex contained cells able to form neurospheres.
These results indicate the specific presence of cancer stem-like
cells within the SP fraction of solid tumors.
Neurospheres Are Enriched in the Side Population,
which Mainly Results from the Activity of ABCG2
Since the SP in vivo accounts for a small fraction of the cells and
contains a high number of endothelial cells, we used neural stem
cell culture to enrich for cancer stem-like cells from mouse
gliomas. Cancer stem-like cells cultures were obtained by trans-
ferring cells isolated from different PDGF-driven tumors into
neurosphere medium. These spheres contained cells that
predominantly stained with antibodies to stem cell markers
such as nestin, Oct-4, Sox-2, musashi, and also to some level
to ABCG2 (Figure 2B). ABCB1, ABCC1, and ABCG2 are the three
main transporters known to posses the ability to exclude drugs
and to be present in stem cells of different tumor types. Analysis
of ABC transporter expression in tumor cells cultured in neuro-
sphere medium, as opposed to DMEM supplemented with
10% FBS, showed that ABCG2 is the only transporter228 Cell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc.
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(A) Culture of sorted low SP, SP, and MP cells in neurosphere medium shows that only SP cells are able to form neurospheres. Error bars are mean ± SEM.
(B) Total neurosphere cultures prepared from PDGF-induced tumors stain positive for various stem cell markers such as nestin, Oct4, Sox2, Musashi, ABCG2,
and GFAP. Bars, 25 and 50 mm.
(C) Q-RT-PCR showing relative ABC transporter mRNA levels in neurospheres as compared to the same cells cultured in DMEM supplemented with 10% FCS.
Note that only ABCG2 expression increases under stem cell conditions. Error bars are mean ± SEM.
(D) Hoechst dye exclusion assay on neurospheres reveals a high percentage of SP cells. Incubation with Verapamil partially abolished the SP fraction while
Pantoprazole and Fumitremorgin C (FTC) almost totally abolished the SP phenotype.
(E) Sorted SP cells isolated from neurospheres are highly resistant to mitoxantrone as compared to the total population, but were sensitized by the coincubation
with FTC. Error bars are mean ± SEM.upregulated in glioma cancer stem-like cells; the expression of
ABCB1a/b and ABCC1 was even reduced (Figure 2C). This
observation is consistent with the concept that the ABCG2 trans-
porter is the most specific stem cell marker of this family (Islam
et al., 2005). As the SP represents a high concentration of
stem cells, Hoechst dye exclusion of neurospheres was
expected to yield a large SP fraction. As expected, 10% to
20% of cells from neurospheres were located in the SP fraction
(Figure 2D). There were no CD31-positive cells in neurosphere
culture, indicating that the SP phenotype is not due to the pres-
ence of endothelial cells (data not shown). Q-RT-PCR confirmed
the higher level of ABCG2 expression in the SP fraction
(Figure S1C). The relative expression of ABCB1a and ABCC1
was also found to be increased in the SP fraction, which is not
surprising given that Hoechst dye is a substrate for various
ABC transporters (Figure S1C). We then preincubated neuro-
spheres with fumitremorgin C (FTC), a potent and specific
inhibitor of ABCG2 (Rabindran et al., 2000), to determine the
contribution of ABCG2 to the SP phenotype. Addition of FTC
reduced the SP phenotype from 22% to 4%, confirming the
dominant role that ABCG2 plays in the SP phenotype
(Figure 2D). Pantoprazole, known to block ABCG2 activity (and
to a lesser extent ABCB1), also diminished the amount of SP
cells to 7% of total cells. Verapamil, a nonspecific inhibitor of
ABC transporters (and more potent inhibitor of ABCB1 and
ABCC1) only reduced the SP fraction to 11%.SP Cells Isolated from Neurospheres Propagate
the Neurosphere Phenotype and Are Resistant
to Mitoxantrone
We next analyzed the self-renewal capacity of SP cells using the
neurosphere-forming assay. Neurospheres cultured from four
different PDGF-induced glioma-bearing mice were dissociated
and stained with Hoechst. SP and MP cells were then sorted
and cultured in neurosphere medium. SP cells from neuro-
spheres are endowed with a higher ability to generate secondary
neurospheres: 20.4 ± 1.3% of SP cells as compared to 4.6 ±
0.4% of MP cells (p < 0.001) (Figure S1D). The rare spheres
formed from the MP fraction may result in part from the low
contamination with SP cells, as shown by the reanalysis of the
sample directly after sorting (Figure S1D, right panel); it is also
possible that rare stem cells exist that do not efflux Hoechst
dye. Overall, these data demonstrate that SP cells are enriched
in cancer stem-like cell characteristics and self-renewal ability.
We then evaluated the drug resistance property of the side
population; SP and MP neurosphere cultures were exposed to
50 nMmitoxantone and analyzed for their proliferation rate using
anMTT assay. Mitoxantrone has been reported to be a substrate
of ABCG2, and its efflux by the transporter is a determinant
mechanism of drug resistance. As stated above, MP cells
possess a lower ability to form neurospheres; consequently,
the initial proliferative rate of these cells was below the detection
limit of the assay. We found that SP cells are more resistant toCell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc. 229
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The Side Population of Glioma Stem CellsFigure 3. Loss of PTEN and Temozolomide Treatment Increase the SP Fraction; SP Cells with PTEN Loss Are Highly Tumorigenic
(A) Loss of PTEN in neurospheres strongly increases the SP phenotype, which is partially blocked by the incubation with the PI3K inhibitor LY294002. Long-term
treatment of neurospheres with 100 mM temozolomide induces an increase in the amount of SP cells, which is greatly favored by PTEN deletion.
(B) ABCG2 (red) localizes at the cell membrane in untreated cells as compared to the cytoplasmic staining upon treatment with LY294002.
(C) Kaplan-Meier survival curve shows that SP cells isolated from neurospheres with PTEN loss possess a higher tumorigenic potential than the MP cells; temo-
zolomide treatment increases the tumorigenicity of SP cells.
(D) Q-RT-PCR in neurospheres showing increased nestin expression after treatment with temozolomide; MGMT expression is enriched in SP cells. Error bars are
mean ± SEM.
(E) Western blot analysis for ABCG2 indicates that LY294002 (LY) and temozolomide (T) do not modulate ABCG2 expression as compared to DMSO treated cells.mitoxantrone and were sensitized by concurrent blockade of
ABCG2 using FTC (Figure 2E). In SP cells, the quantitative
decrease in proliferation induced by incubation with both mitox-
antrone and FTC did not reach that produced by mitoxantrone
alone in total neurosphere culture. This suggests that additional
mechanisms, other than efflux by ABC transporters, might also
be involved in drug resistance. One possibility proposed recently
(Bao et al., 2006) involves an increased capacity of stem cells for
DNA-damage repair. Taken together, these data indicate that
ABCG2 is expressed in neurospheres, allows for the selection
of SP cells, and participates in resistance to chemotherapy.
Loss of PTEN Increases the SP Fraction and Highly
Favors the MDR Phenotype
Akt has been shown to regulate the SP phenotype in bone
marrow cells, and similar effects were reported in breast cancer
cells after PTEN loss (Zhou et al., 2007). To test whether loss of
PTEN could modulate the SP in gliomas, we compared the
amount of SP cells in neurospheres isolated from PDGF-induced
gliomas in both PTEN intact and PTEN-deficient mice (by Cre
recombinase). Five different tumors were analyzed in each
group; loss of PTEN and increased in pAKT level in neurospheres
were confirmed by immunoblot (Figure S1E). The loss of PTEN
produced a pronounced increase of the SP fraction; the PTEN-
deleted cells contained 33.1 ± 4.0% SP cells versus 15.5 ± 1.5%230 Cell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc.in PTEN intact (Figure 3A). While mitoxantrone induced an
arrest of PDGF-neurospheres in the G0/G1 phase, the higher
level of SP cells in PTEN-deleted cells resulted in increased
resistant to mitoxantrone, an effect that was reversed by incuba-
tion with FTC (Figure S1F). Incubation of neurospheres with the
PI3 kinase inhibitor LY294002 (20 mM) strongly reduced the
proportion of SP cells in both PDGF (3.6 ± 0.4%-fold) and
PDGF/PTEN deleted (3.0 ± 0.7%-fold) tumors, confirming that
PI3K regulates the SP phenotype (Figure 3A). We confirmed
this observation using the PI3K inhibitor GDC-0941 and found
that it reduced the amount of SP cells in a dose-dependent
manner (Figure S2A). No substantial difference in ABCG2
protein and mRNA levels were detected upon treatment with
LY294002 (Figure 3E and Figure S2B), suggesting that PI3K
activity regulates ABCG2 function rather than its expression.
None of the other ABC transporters tested showed a difference
in mRNA levels after treatment with LY294002 (Figure S2B).
LY294002 has been reported to induce a translocation of
ABCG2 from the plasma membrane to the endoplasmic retic-
ulum. To determine if such a mechanism also occurs in glioma
cancer stem-like cells, we stained PTEN-deleted cells for
ABCG2 after 16 hr treatment with LY294002. We observed
a change in the localization of the protein, presenting a diffuse
cytoplasmic pattern as compared to the membrane staining in
the control (Figure 3B).
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We then determined the relative tumorigenic potential of side
population cells isolated from neurospheres derived from
PDGF-driven PTEN-deleted tumors. We have already demon-
strated in our mouse model that loss of PTEN correlates with
higher-grade and tumor latency. Following Hoechst staining,
we sorted SP and MP cells: 13 104 cells were injected intracra-
nially in newborn pups (20mice per group).Whenmice presented
symptomsof intracranial pathology suchas lethargy,weight loss,
and macrocephaly, the animals were sacrificed and evaluated
for tumors by histology. In general, these secondary tumors
exhibited features of high-grade gliomas such as microvascular
proliferation and pseudopalisading necrosis (Figure S2C). In
two cases, we noticed subcutaneous proliferation on the head
ofmice injectedwithMP cells, but not in the cranial lesions; these
mice were not included in the analysis. Kaplan-Meier survival
curves indicated that in the absence of PTEN, SP cells are highly
tumorigenic as compared to MP cells, showing higher tumor
frequency and shorter latency (p < 0.0001) (Figure 3C). As
observed for the low sphere-formation ability of MP cells, tumor
formation induced by this fraction might also result from the
contamination with SP cells or the presence of stem-like cells in
the non-SP compartment.
We verified that the lower frequency of tumors obtained after
the injection of MP cells was not a result of Hoechst dye toxicity
by measuring cell viability 10 days after sorting and culture of the
SP andMP, as well as the total cell population stained or not with
the dye. In all cases, viability was not affected (Figure S2D). In
parallel, we incubated total neurosphere culture from PDGF-
induced tumors for 90 min with Hoechst and analyzed the cell-
cycle distribution 10 days later. No apoptosis or differences in
cell-cycle distribution were observed (Figure S2D, right panel).
To determinewhether ABCG2 is itself tumorigenic, we injected
DF1 cells transfected with a RCAS-ABCG2 vector into Ntv-a/
Ink4a/Arf/newbornpupsandassessed the tumor incidence.
ABCG2 activity was confirmed by the ability of transfected
DF1 cells to exclude Hoechst dye (Figure S3A). Of the 25 mice
tested, no tumors or lesions were detected up to 6 months after
injection. By contrast, RCAS-PDGF induces high-grade gliomas
in the vast majority of mice with this background in less than
12 weeks. Unlike the high-grade gliomas formed in the Ntv-a/
Ink4a/Arf/ mice, RCAS-PDGF induces low-grade gliomas
in Ntv-a/wt mouse background (Ink4a/Arf intact) (Dai et al.,
2001). Therefore, we determined if ABCG2 could increase tumor
incidence and grade or reduce latency time in these mice with
lower grade tumors. Coinjection of DF1 cells expressing RCAS-
PDGF and RCAS-ABCG2 produced the same number and grade
of tumors as for RCAS-PDGF alone. These data suggest that
ABCG2 is not tumorigenic by itself, nor does it enhance PDGF
tumorigenicity. Rather, the SP phenotype, which mainly results
from ABCG2 activity, is a useful marker to isolate tumor-initiating
cancer stem-like cells.
Temozolomide In Vitro Induces an Increase of the SP
Fraction in Neurospheres
Recent work has suggested that cancer stem-like cells are the
source of chemotherapy resistance in cancer with the potential
to repopulate a tumor after therapy. Temozolomide, in combina-
tionwith radiation, is currently the standard treatment for patientswith glioblastomas. To investigate whether temozolomide could
induce the MDR phenotype in cancer stem-like cells, we evalu-
ated the resistance to temozolomide of neurospheres derived
from PDGF-induced gliomas. We performed a step-wise expo-
sure with increasing doses of temozolomide over 2 weeks and
assessed for the SP fraction. Four different tumors were
analyzed: the treatment led to a 1.5 ± 0.04-fold increase in the
SP fraction, reaching up to 30% of total cells (p < 0.05)
(Figure 3A). As our data above demonstrate that PTEN loss in
gliomas increases SP cell number, we hypothesized that PTEN
loss leads to greater temozolomide resistance. Indeed, long-
term treatment of PDGF/PTEN-deleted neurosphereswith temo-
zolomide induced a 2.2 ± 0.1-fold increase in the SP fraction as
compared to the untreated spheres; in some cases, the amount
of SP cells even reached 75% of total cells (Figure 3A). The fold
increase in SP induced by temozolomide was significantly higher
in neurospheres isolated from PDGF/PTEN-deleted tumors than
PDGF alone (p < 0.05). These data suggest that loss of PTEN has
an important role in the regulation of the MDR phenotype, espe-
cially under the stress of cytotoxic therapy. We then sorted
the SP cells from the temozolomide-treated neurospheres and
assessed for their tumorigenic potential (8 mice per group;
same number of implanted cells). We found that temozolomide
treatment significantly shortened the tumor latency time as
compared to the SP cells isolated from untreated neurospheres
(p<0.01) (Figure 3C). Theobserved increase inSPcells produced
by temozolomide treatment is accompanied by a parallel
increase in nestin-expressing cells, as shown by a 2.24 ±
0.62-fold elevation in nestin mRNA (p < 0.05) (Figure 3D, left
panel). These observations demonstrate that temozolomide
enrich for highly tumorigenic cells and cells with stem-like cell
characteristics.
To investigate whether the elevated SP phenotype could also
result from increased ABCG2 expression, time-course assays
with temozolomide were performed, and the neurospheres
were analyzed for ABCG2 expression at the protein and mRNA
levels. Short-time exposures (2 to 24 hr) did not produce any
changes in ABCG2 protein or mRNA levels, nor was the activity
of the transporter affected, as measured by mitoxantrone efflux
(Figure 3E; Figures S2E and S2F). In summary, the above data
are consistent with temozolomide either being a substrate for
ABCG2 or alternatively with temozolomide treatment inducing
an enrichment of naturally resistant stem cells through a mecha-
nism other than direct selection.
Localization of ABCG2 at the Cell Membrane Regulates
Its Activity and Depends on Posttranslational
Modifications
To investigate whether the increase in SP phenotype induced by
temozolomide resulted from an active transport of the drug by
ABCG2, we generated a human glioma cell line U87-MG that
stably expressed hABCG2 (U87-ABCG2). While neither SP cells
nor ABCG2 protein were found in cells infected with the empty
vector (U87-Cont), those stably expressing ABCG2 displayed
a band at 72 kDa and a clear SP fraction (i.e., 7%) that was
blocked by FTC (Figures 4A and 4B; Figure S3B). Western blot
of ABCG2 from lysates derived from these cells showedmultiple
bands, suggesting the acquisition of posttranslational modifica-
tions. A sample highly enriched for SP cells derived from doubleCell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc. 231
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a high MW form of the ABCG2 protein. In contrast, this band
was absent in non-SP cells, indicating that additional posttrans-
lational modifications are associated with ABCG2 activity in SP
cells. ABCG2 is known to be N-glycosylated at Asn596, although
this modification is not essential for its activity (Diop and Hry-
cyna, 2005). We tested whether the higher MW form observed
in the sorted SP cells line could result in part from glycosylation.
PGNase treatment of SP cell extracts produced a marked
decrease in the apparent MW, demonstrating that this ABCG2
glycoform is more extensively N-glycosylated (Figure S3D).
ABCG2 is known to be expressed at the cell membrane and
at the endoplasmic reticulum. We initially hypothesized that
the band at higher MW detected by WB corresponds to the
active form of the protein, which localizes to the cell membrane.
To address this question, we performed immunostaining for
ABCG2: the protein was detected both in the cytoplasm and at
the cell membrane in ABCG2-SP2 cells, while it localized only
in the cytoplasm in non-SP cells (MP2) (Figure 5A). As a second
approach,weusedFACSanalysiswith ananti-hABCG2antibody
that recognizes only the cell-surface protein (without permeabili-
zation); we observed a shift in staining intensity in SP2 cells as
Figure 4. U87MG-ABCG2 Stable Cell Line Is Resistant to Mitoxan-
trone, but Not Temozolomide
(A) U87-ABCG2 cell line presents a 72 kDa band, accompanied by posttrans-
lational modifications, that correlates with high ABCG2 activity (B). (C) The
SP2 cells (SP cells enriched by two-sorting) are highly resistant to mitoxan-
trone, but not temozolomide.232 Cell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc.compared to non-SP cells as well as those infected with the
empty vector (median staining intensity was 9.5 for SP cells
versus 3.3 for non-SP cells) (Figure 5A).
Temozolomide Is Not a Substrate for ABCG2but Induces
Its Activity by a Mechanism Other Than Selection
Our observation that temozolomide selects for higher SP could
simply be explained by the drug itself being a substrate for
ABCG2. To test this hypothesis, we used the ABCG2-expressing
U87-MG cell line to test for temozolomide resistance. Mitoxan-
trone served as control and we assessed the cell-cycle distribu-
tion after 48 hr of incubation. In cells infected with the empty
vector, 25 nM mitoxantrone induced a clear G2M arrest, while
the U87-ABCG2 cell line was resistant to the drug (Figure 4C).
We then analyzed cell-cycle distribution after treatment with
temozolomide; we were unable to detect any differences
between the two cell lines, indicating that ABCG2 expression
does not provide any resistance to temozolomide (Figure 4C).
As a second approach, we performed a competition assay in
whichanexcessof afirst substratecompetitivelyblocks theefflux
of a dye. As a control, wemeasured the intracellular accumulation
of mitoxantrone, with and without coincubation with 10 mg/ml
Hoechst. The dye induced a shift in the intracellular fluorescence
of mitoxantrone (Figure S3C). By contrast, temozolomide was
unable to produce any changes in mitoxantrone accumulation,
even at very high concentration (1.2 mM). Taken together, these
results suggest that although temozolomide induces SP pheno-
type in glioma cells, it is not a substrate for ABCG2.
To determine which mechanism contributes to the increase in
the SP phenotype, we looked at the level of O6-methylguanine
DNA methyltransferase (MGMT); increased expression and
elevated activity of MGMT has been shown to be a key mecha-
nism involved in the resistance of gliomas to temozolomide
(Kitange et al., 2008). We compared the MGMT mRNA level in
SP and MP cells isolated from PDGF/PTEN-deleted neuro-
spheres (prepared from four different tumors). We found that
MGMT expression is increased by 3.1-fold in SP cells (p < 0.01)
(Figure 3D, right panel), consistent with the resistance of SP cells
to temozolomide. The elevation of MGMT expression in SP cells
was accompanied by a 25% increase in temozolomide resis-
tance as compared to MP cells (Figure S2E).
The PI3K and Akt Pathways Regulate ABCG2 Activity
The data showing that PTEN loss increases the SP suggest that
the PI3K pathway regulates ABCG2 activity. To shed light on
this issue, we used the sorted SP cells from U87-ABCG2 cell
line and assayed for their ability to efflux mitoxantrone by FACS
analysis. Cells were treated for 6 hr with Akt inhibitors (except
2 hr for Akt inhibitor IV) and stained for 1 hr with mitoxantrone.
As SP2 cells possess high ability to effluxmitoxantrone, the intra-
cellular intensity was low (i.e., median fluorescence intensity of
2.06) as compared to the U87-Cont cells (median value of 9.19)
(Figure 5B). We detected similar effects to the regulation of the
SP phenotype in neurospheres: incubation with the PI3 kinase
inhibitor LY294002 andAkt inhibitor IV totally abolished the ability
of the transporter to exclude the drug (median value of 8.57 and
7.08 respectively). Perifosine (5 to 45 mM), an inhibitor of the Akt
pathway, partially lowered the extent of mitoxantrone efflux
(median value of 5.68), while the mTOR inhibitor Rapamycin
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that blocking of PI3K in these cells using LY294002 induced
a translocation of ABCG2 from the cell membrane to the cyto-
plasm, as shown by intracellular immunofluorescence staining
of the transporter and reduction in cell surface stainingmeasured
byFACSanalysis (median fluorescence value of 5.6 as compared
to 9.5 for untreated cells) (Figure 5A). These results suggest that
the effect of PTEN loss on the elevation of ABCG2 activity shown
above is due to thePI3K/Akt activity, but notmTOR,potentially by
the modulation of ABCG2 localization.
The PI3K/Akt Pathway Regulates the SP Phenotype
in Human Neurospheres as Well
We then evaluated the SP fraction of neurospheres prepared
from four different humanGBMspecimens. Human tumor neuro-
spheres exhibited a clear SP fraction, which was blocked by
coincubation with FTC, indicating that ABCG2 also participates
in the SP phenotype of human cancer stem-like cells (Figure 5C
and Figure S3E). Inhibition of PI3K with LY294002 substantially
reduced the SP fraction, while perifosine was effective mainly
against the SP cells located at the bottom of the fraction. These
data suggest that the PI3K and Akt pathways regulate the SP
Figure 5. PI3K/Akt Pathway Regulates
ABCG2 Activity in U87MG Stable Cell Line
and the SP Phenotype of Human Neuro-
spheres
(A) Immunostaining for hABCG2 (red) shows
a membrane staining in SP2 cells versus a cyto-
plasmic staining in MP2 cells; ZO-1 (green) delim-
itate the membrane. In the right panel, FACS anal-
ysis using cell surface hABCG2 antibody confirms
high staining intensity in SP2 cells. Blocking of
PI3K with LY294002 induced a change in ABCG2
localization, from the cell membrane to the cyto-
plasm.
(B) Mitoxantrone exclusion assay in SP2 cells after
incubation with LY294002, Akt inhibitor IV, perifo-
sine, and rapamycin. Blocking of the PI3K and Akt
pathways abolished the ability of ABCG2 to efflux
mitoxantrone.
(C) Hoechst staining of human neurosphere culture
shows the presence of a SP that was blocked by
FTC. Treatment with LY29004 totally abolished
the SP fraction, while perifosine displayed
a stronger effect in blocking the lower SP fraction.
(D) H&E of nudemice injected with SP cells isolated
from human GBM neuropsheres.
(E) Kaplan-Meier survival curve shows that SP cells
isolated from human neurospheres are more
tumorigenic then MP cells.
phenotype in human neurospheres and
underline a common mechanism of regu-
lation between human and mouse cancer
stem-like cells.
We finally assessed the tumorigenic
potential of SP and MP cells isolated
from human GBM neurosphere cultures.
Two hundred thousands cells were ster-
eotactically injected to the brain of nude
mice (10 per group). Animals were sacrificed when presenting
symptoms and evaluated for tumors by histology. All mice devel-
oped tumors that resemble features of human high-grade
gliomas (Figure 5D). Although tumors eventually formed in the
majority of mice in both populations, the latency for tumor forma-
tion was significantly shorter in the SP population (p < 0.01) when
compared to the MP cells, consistent with the mouse data
(Figure 5E).
DISCUSSION
Both the relative rarity of cancer stem-like cells in tumors and the
absence of reproducible specific markers for glioma stem cell
limit identification and isolation of this important cellular subpop-
ulation. In this study, we used the efflux of Hoechst dye, which
allows identification of the side population phenotype, to isolate
both tumor endothelial cells and tumor-initiating cells with
cancer stem-like cells characteristic from mouse and human
glioblastomas.
One of the main molecular changes accompanying progres-
sion of gliomas to high grade, which increased stem cell char-
acter and enhances resistance to chemotherapy, is the loss ofCell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc. 233
Cell Stem Cell
The Side Population of Glioma Stem CellsPTEN and consequent elevation of Akt pathways activity
(Hu et al., 2005). Increased activity of the Akt pathway is associ-
ated with many forms of resistance and is found in a population
of radiation resistant cancer stem-like cells in medulloblastomas
where Akt inhibition appears to sensitize the cell population for
radiation-induced apoptosis (Hambardzumyan et al., 2008b).
Our data provide further connections between the Akt pathway,
stem-like character, and therapeutic resistance, suggesting that
in addition to the induction of radiation resistance in medullo-
blastomas, activation of this pathway also enhances the ability
of glioma cancer stem-like cells to expel drugs.
Although temozolomide is currently the first-line standard of
care for the treatment of glioma, temozolomide increases the
aggressiveness of surviving glioma cells by several mechanisms.
We report in this study that temozolomide increases the number
of SP cells, especially from PTEN-deleted gliomas. If temozolo-
mide were a substrate for ABCG2, the data would suggest
a selection for cells that efflux the drug. However, our data and
other (Chua et al., 2008) indicate it is not an ABCG2 substrate,
implying that the increase in the SP phenotype might result
from the enrichment of cells with stem-like properties. Therefore,
in the process of increasing the number of cells in tumors with
stem-like properties, temozolomide may render surviving cells
even more resistant to subsequent treatment with drugs that
are substrates for ABCG2. Ubiquitous distribution of temozolo-
mide was reported into all human tissues, including the brain,
suggesting that the BBB efflux pumps do not contribute to temo-
zolomide resistance (Ostermann et al., 2004). Interestingly, we
found that SP cells overexpress MGMT as compared to MP
cells. The MGMT enzyme is responsible for the removal of alkyl
groups induced by alkylating agents, suggesting that the resis-
tance to temozolomide observed in glioma cancer stem-like
cells might be related in part to its alkylating activity. A general
trend toward high expression of several DNA repair genes,
including MGMT, has been demonstrated in heamatopoeitic
stem cells (Casorelli et al., 2007), contributing to the higher
drug resistance of cancer stem-like cells.
The SP cells from PTEN-deleted neurospheres were substan-
tially more tumorigenic than the non-SP cells, as shown by
a significant decrease in tumor latency. Moreover, temozolo-
mide further enriched for highly tumorigenic cells, suggesting
that temozolomide treatment could favor tumor recurrence.
Because the SP phenotype in glioma cancer stem-like cells is
mainly mediated by ABCG2, as shown by the almost complete
abolition of the SP phenotype when blocking of its function,
we subsequently studied the oncogenic potential of ABCG2.
Although ABCG2 expression appears not to be oncogenic itself,
selecting for the Hoechst dye exclusion phenotype, conferred by
this transporter, highly enriches for tumor-promoting cells.
Cancer stem-like cells simultaneously present impaired onco-
genes/tumor suppressors expression and drug resistance
abnormalities, two distinct properties that can bemutually exclu-
sive. ABCG2’s main function is to efflux compounds to protect
the cells from cytotoxic agents, a drug-resistance characteristic
of cancer stem-like cells, which defines the SP phenotype.
One focus of the current study was to elucidate the mecha-
nisms regulating ABCG2 function. We noticed that although
PI3K activity and temozolomide treatment changed the activity
of ABCG2 in neurospheres, the expression levels of the mRNA234 Cell Stem Cell 4, 226–235, March 6, 2009 ª2009 Elsevier Inc.and protein were unaffected. In mouse and human, inhibiting
the PI3K/Akt pathway, but not mTOR, strongly decreased the
activity of the transporter by modulating its localization at the
cell membrane. These data suggest that therapeutic blockade
of either PI3K or Akt might reduce ABCG2 function in cancer
stem-like cells in vivo and improve chemotherapy efficacy for
drugs that are substrates of this transporter.
In summary, our studies support a role for ABCG2 as a molec-
ular determinant of the side population phenotype in glioma
stem-like cells, a phenotype characterized by both tumorigenic
and chemoresistant properties. Furthermore, we report that
loss of the tumor suppressor PTEN, an important genomic alter-
ation associated with glioma progression, greatly increases the
SP and further enhances the MDR phenotype upon the standard
treatment with temozolomide.
EXPERIMENTAL PROCEDURES
Hoechst 33342 Staining and Flow Cytometry
Cells were dissociated from normal brain cortex or tumors and resuspended at
106 cells/ml in Hank’s balanced salt solution containing 2% fetal bovine serum
(FBS), 10 mM HEPES, 25 U/ml penicillin G, and 25 mg/ml streptomycin. Cells
were preincubated at 37C for 30 min with or without 100 mM verapamil
(Sigma-Aldrich, St. Louis), 25 mMpantoprazole (MSKCC), or 5mM fumitremorgin
C (Sigma-Aldrich) to inhibit ABC transporters and were incubated for 90 min at
37C with 5 mg/ml Hoechst 33342 (Sigma-Aldrich). Cells were incubated on ice
for 10 min and washed with ice-cold HBSS. For immunostaining, cells were
blocked with normal goat serum and were incubated 30 min on ice with FITC
anti-mouse CD31 (1:100), PE anti-mouse CD133 (1:100), PE anti-mouse
CD11b (1:100) (eBioscience, San Diego, CA, USA), and anti-A2B5 (1:200)
(R&D Systems, Minneapolis, MN USA) followed by Streptavidin-Phycoerythrin
(1:400) (R&D Systems). FITC or PE isotype controls were used as negative
control (1:100). For staining of U87MG cell line, cells were trypsinized, blocked
for 15min at room temperaturewith 1 mgmouse IgG/105 cells, and incubated 30
min on ice with APC anti-hABCG2 or APC isotype control (1:10). Hoechst dye
was excited at 407 nm by trigon violet laser, and its dual wavelengths were de-
tected using 450/40 (Hoechst 33342-Blue) and 695/40 (Hoechst 33342-Red)
filters. FITC and PE were excited at 488 nm by an octagon blue laser, and fluo-
rescence was detected using 530/30 and 675/20 filters, respectively. Fl4 exci-
tation of APC was at 633 nm, and emission was at 660 nm. Dead cells were
excluded by gating on forward and side scatter and eliminating PI-positive pop-
ulation. The data were analyzed by FlowJo (Ashland, OR, USA).
Intracranial Injection of Mouse and Human Glioma Cells
For assessment of tumorigenicity, mouse or human neurospheres were
stained with Hoechst 33342 for subsequent sorting of SP and non-SP cells.
1 3 104 mouse cells were injected into the newborn pups cortex (Ntv-a/
Ink4a/Arf/ PTENflox mice).
For human cells, injections were performed using stereotactic fixation
device (Stoelting, Wood Dale, IL). Mice used for these experiments were
nude at 5 to 6 weeks old. Mice were anaesthetized by i.p. injections of
ketamine (0.1 mg/g) and xylazine (0.02 mg/g). One microliter of 2 3 105
SP- and MP-sorted cell suspensions were delivered using 30-gauge needle
attached to Hamilton syringe. Locations were determined by using mouse
atlas (Franklin and Paxinos, 2007). Coordinates for injections in the right hemi-
sphere are AP 2 mm from bregma, lat. 0.5 mm (left or right), and depth 1 mm
from dural surface. Mice were monitored carefully for strong symptoms of
tumor development and where sacrificed (lethargy and head tilt).
Flow Cytometric Detection of Mitoxantrone Accumulation
and Cell-Cycle Analysis
The ability of neurospheres and U87MG cell lines to extrude mitoxantrone was
measuredwithaFACScaliburflowcytometer (BectonDicksonMedicalSystems,
Sharon, MA, USA), equipped with an argon laser. Cells were preincubated with
5mMfumitremorginC for 30min, and3mMmitoxantronewasaddedand thecells
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PBS, andmitoxantrone fluorescenceof 10,000-gatedeventswas logarithmically
measured at a laser-excitation wavelength of 635 nm through a 670 nm band-
pass filter. Measurements were performed on duplicate samples, and experi-
ments were performed in triplicate.
Statistical Analysis
Comparison between two groupswasmade using Student’s t test. Data repre-
sent themean ± SD. p values of < 0.05were considered statistically significant.
The differences in in vitro growth among treatmentswere tested using the anal-
ysis of covariance (ANCOVA). For Kaplan-Meier survival curves, the Tarone-
Ware method was used.
SUPPLEMENTAL DATA
The Supplemental Data include one table, three figures, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://www.cell.com/cell-stem-cell/supplemental/
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